# Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)

> **NCT00313209** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 933 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00313209
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-07
- **Final completion:** 2008-02
- **Target enrollment:** 933 (ACTUAL)
- **Last updated:** 2016-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313209, "Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00313209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*